Medinotec Inc. Reports Q2 Fiscal 2026 Revenue of $3.2 Million, Net Income Declines

Medinotec Inc. reported its financial results for the second quarter of fiscal 2026, revealing a revenue of $3.2 million for the three months ended August 31, 2026, a slight decrease from $3.24 million in the same period last year. For the six months ending August 31, 2026, the company generated $5.85 million in revenue, up from $5.37 million in the prior year. The cost of goods sold increased significantly, leading to a gross profit of $1.56 million for the quarter, down from $1.98 million in the previous year. The net income for the quarter was $40,866, a decrease from $346,566 in the same quarter of 2025.

The company experienced notable changes in its operational expenses, which totaled $1.36 million for the three months ended August 31, 2026, compared to $1.45 million in the same period last year. The increase in depreciation and amortization expenses, which rose to $21,824 from $7,497, contributed to the overall decline in profitability. Additionally, general and administrative expenses increased to $835,893 from $706,597, reflecting higher operational costs. The company’s income from operations was $202,723, down from $528,565 in the prior year.

Medinotec's strategic developments included the ongoing evaluation of market opportunities and the management of its distribution channels. The company continues to operate primarily in South Africa and the United States, with plans to explore additional markets. The company has also received FDA 510(k) clearance for its Trachealator and Outflo products, which are expected to enhance its product offerings and market presence. As of August 31, 2026, the company reported a total of 11,755,548 shares outstanding, consistent with the previous period.

Operationally, Medinotec reported an increase in accounts receivable, which rose to $2.62 million from $2.35 million, indicating a growing customer base. However, the company noted that one major customer accounted for approximately 92% of its accounts receivable, highlighting a concentration risk. The total assets of the company increased to $6.95 million from $6.81 million, driven by a rise in cash and inventory levels. The company’s employee headcount remained stable, supporting its operational activities.

Looking ahead, Medinotec management expressed confidence in the company’s ability to continue as a going concern for at least the next twelve months. The company plans to focus on enhancing its product lines and expanding its market reach, while also managing operational costs to improve profitability. The outlook remains cautiously optimistic as the company navigates market conditions and seeks to capitalize on growth opportunities in the medical device sector.